{"filings":[{"id":2051558,"accession_number":"0000927066-26-000105","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2026-08-04T20:08:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q2 2026 EPS $4.02, revenue $3.55B; net income up 34% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $3.554B; operating income $579M; diluted EPS $4.02.","Net income $265M vs $198M in Q1 2026; six-month net income $463M vs $362M YoY.","Operating cash flow $490M; free cash flow $256M.","Incurred $500M Term Loan B-2, used to repay revolver; repurchased 2.2M shares at $154.95 avg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":919236,"accession_number":"0001206774-26-000316","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2026-06-08T20:33:52+00:00","items":["1.01","2.03","5.07","9.01"],"status":"ready","headline":"DaVita adds $500M senior secured term loan B facility via Ninth Amendment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Incremental Tranche B-2 Term Loans of $500M added to existing credit agreement; maturity May 2031.","Interest at Term SOFR + 175 bps or Base Rate + 75 bps, at borrower's option.","Proceeds used to repay a portion of outstanding revolving loans, pay fees, and for general corporate purposes.","JPMorgan acts as administrative agent; nine lenders participated as joint lead arrangers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99845,"accession_number":"0000927066-26-000060","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q1 2026 adj EPS $2.87 vs $2.00 YoY; revenue $3.416B, repurchased 3M shares","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP and adjusted diluted EPS $2.87, up 44% YoY from $2.00; down sequentially from $3.40 in Q4 2025.","Consolidated revenue $3.416B; operating income $482M; operating cash flow $321M; free cash flow $140M.","Repurchased 3.0M shares at avg price $133.70 per share during Q1 2026.","CEO Javier Rodriguez highlighted clinical excellence and durable results; net income from continuing ops $198M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":3415548000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116096,"accession_number":"0000927066-26-000004","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q4 adj. EPS $3.40 vs $2.51 Q3; full-year net income down YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $3.620B, operating income $561M, adj. operating income $586M.","Q4 adj. diluted EPS $3.40; full-year 2025 adj. diluted EPS $10.78 (2024: $9.68).","Full-year 2025 net income from continuing ops $722M ($9.51 diluted EPS) vs 2024 $936M ($10.73).","Repurchased 2.7M shares in Q4 at avg $122.78; 12.7M shares in 2025 at avg $140.09.","Refinanced Term Loan A-1 and revolver; earlier in 2025 issued $6.75% senior notes due 2033."],"consensus_eps_estimate":null,"consensus_eps_actual":9.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":13643069000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132540,"accession_number":"0001206774-25-000750","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"DaVita refinances $3.5B in credit facilities; JPMorgan replaces Wells Fargo as agent","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $2.0B secured term loan A facility (New A-2 Term Facility) and $1.5B secured revolving credit facility (New Revolving Facility).","New facilities refinance existing ~$1.95B term loan and $1.5B revolver both maturing April 2028.","Proceeds used to repay prior facilities, pay fees, and for working capital and general corporate purposes including stock repurchases and acquisitions.","JPMorgan Chase Bank appointed as administrative agent, collateral agent, and swingline lender, replacing Wells Fargo.","New A-2 Term Facility amortizes quarterly beginning March 2026 at 2.5% p.a. first two years then 5.0% p.a. thereafter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132539,"accession_number":"0000927066-25-000163","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q3 2025 EPS $2.04, revenue $3.42B, in line with guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS of $2.04; adjusted diluted EPS of $2.51.","Consolidated revenue of $3.420 billion.","Operating income of $506M; adjusted operating income of $517M.","Operating cash flow $842M; free cash flow $604M.","Repurchased 3.3 million shares at average $140.67 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":6.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":10023282000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149073,"accession_number":"0000927066-25-000154","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DaVita board authorizes additional $2 billion share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized $2,000,000,000 in additional repurchasing authority under existing share repurchase program.","New Authorization does not replace the $1.0B September 2024 authorization; both remain active with no expiration.","Repurchases may be executed via open market, accelerated share repurchases, tender offers, or Rule 10b5-1 plans.","Company retains right to suspend or discontinue either authorization at any time, subject to credit facility limits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149072,"accession_number":"0000927066-25-000122","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q2 2025: EPS $2.58 ($2.95 adj.); revenue $3.38B; $1B notes issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS $2.58 ($2.95 adjusted); net income $199M vs Q1 $163M.","Revenue $3.38B; operating income $538M; adjusted operating income $551M.","Issued $1.0B of 6.75% senior notes to repay revolving credit line.","Repurchased 3.1M shares at average price $144.00 per share.","Operating cash flow $324M; free cash flow $157M."],"consensus_eps_estimate":null,"consensus_eps_actual":4.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":6603055000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149071,"accession_number":"0001193125-25-160501","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"DaVita reprices $1.88B term loan B, cuts margin 25 bps, adds $250M incremental debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Seventh Amendment to Credit Agreement reprices $1.628B Extended Tranche B-1 Term Loans into Tranche B-2 at 175 bps (Term SOFR) and 75 bps (Base Rate), down from 200/100 bps.","Incurs $250M Incremental Tranche B-2 Term Loans; proceeds used to repay $250M of senior secured term A loans maturing April 2028.","Total Tranche B-2 Term Loans outstanding ~$1.88B; new loans mature May 2031, matching original maturity.","Repricing and incremental borrowing effective July 17, 2025; conditions include customary representations and no default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168050,"accession_number":"0000927066-25-000107","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DaVita stockholders elect all nine directors, ratify KPMG, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected with >97% votes cast in favor; broker non-votes ~6.4M shares.","Ratification of KPMG as independent auditor passed with 66,500,682 votes for (95.6% of votes cast).","Advisory approval of executive compensation passed with 59,322,425 votes for (93.9% of votes cast).","69,548,287 shares represented (~90% of outstanding) at the virtual meeting held June 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168049,"accession_number":"0001206774-25-000378","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"DaVita closes $1.0B offering of 6.750% Senior Notes due 2033","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.0B aggregate principal of 6.750% senior notes maturing July 15, 2033.","Net proceeds of ~$986M after discount and fees; will repay $830M of revolver borrowings.","Interest payable semiannually on Jan 15 and Jul 15, starting Jan 15, 2026.","Notes are unsecured, rank equally with existing senior debt; guaranteed by certain domestic subsidiaries.","Redeemable at make-whole premium before Jul 15, 2028; thereafter at specified prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168048,"accession_number":"0001206774-25-000369","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DaVita upsizes and prices $1B of 6.750% Senior Notes due 2033","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offering increased from $750M to $1B aggregate principal; notes priced at 100.000% with 6.750% coupon.","Closing expected May 23, 2025 subject to customary conditions.","Proceeds to repay outstanding revolver borrowings, fees, and general corporate purposes including stock repurchases.","Notes offered under Rule 144A/Reg S; not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168047,"accession_number":"0001206774-25-000368","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DaVita announces private offering of $750M Senior Notes due 2033","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$750M aggregate principal amount of 2033 Senior Notes offered in private placement.","Net proceeds to repay revolving credit facility borrowings and related fees and expenses.","Remaining proceeds for general corporate purposes including stock repurchases, working capital, and capex.","Offering limited to qualified institutional buyers under Rule 144A and non-U.S. persons under Reg S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168046,"accession_number":"0000927066-25-000085","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q1 2025: revenue $3.22B, EPS $2.00, net income $163M down 32% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenues $3.224B; operating income $439M.","Net income $163M, diluted EPS $2.00, down from $240M and $2.65 in Q1 2024.","Operating cash flow $180M; free cash flow negative $45M.","Repurchased 3.7M shares at average price $148.94 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":2.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3223529000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168045,"accession_number":"0001193125-25-079593","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DaVita reports ransomware incident on April 12; operations impacted, patient care continues","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Ransomware encrypted certain network elements; DaVita isolated impacted systems and activated response protocols.","Company working with third-party cybersecurity professionals and notified law enforcement.","Patient care continues but some operations disrupted; interim measures implemented for restoration.","Full scope, nature, and ultimate impact not yet known; duration of disruption uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185274,"accession_number":"0000927066-25-000009","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q4 adjusted EPS $2.24, revenue $3.295B; full year EPS $10.73","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $3.295B; operating income $565M; diluted EPS $3.09 (adjusted $2.24).","FY 2024 revenue $12.816B; net income $936M; diluted EPS $10.73 (adjusted $9.68).","FY 2024 net income up 35% YoY ($936M vs $692M); diluted EPS up from $7.42.","Repurchased 2.3M shares in Q4 at avg $156.46; total 9.8M shares in FY 2024.","CEO: full year adjusted results in top half of guidance range; 2025 outlook positive."],"consensus_eps_estimate":null,"consensus_eps_actual":10.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":12815550000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201861,"accession_number":"0000927066-24-000177","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q3 2024: revenue $3.264B, op income $535M, EPS $2.50, adj EPS $2.59","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $3.264B; operating income $535M; net income $215M ($2.50 diluted EPS).","Adjusted diluted EPS $2.59; nine-month net income $677M vs $541M YoY.","Incurred $1.1B Term Loan A-1 and issued $1.0B 6.875% senior notes; repaid ~$950M Term Loan B-1 and revolver.","Repurchased 2.7M shares at avg $147.20 per share during Q3.","Operating cash flow $810M; free cash flow $555M."],"consensus_eps_estimate":null,"consensus_eps_actual":7.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":9520867000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217897,"accession_number":"0001206774-24-000897","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DaVita appoints David P. Maughan as COO, Kidney Care; Staffieri becomes COO Emeritus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David P. Maughan appointed COO, DaVita Kidney Care, effective September 15, 2024, succeeding Michael D. Staffieri.","Maughan previously SVP overseeing home and hospital services, HR, IT, marketing, and state government affairs.","Employment agreement provides $725,000 base salary and 2024 target bonus of 100% of base salary earned.","Severance includes benefits under DaVita Severance Plan; enhanced to 2-year base salary if Good Cause resignation within 2 years post-change-of-control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217896,"accession_number":"0000927066-24-000162","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"DaVita board approves $2B increase to share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board added $2B in repurchase authority; no expiration date, no obligation to repurchase.","Repurchases may occur via open market, private deals, or existing agreement with Berkshire Hathaway.","Bylaws amended to revise stockholder nomination and meeting procedures; effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217895,"accession_number":"0001206774-24-000784","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"DaVita issues $1.0B of 6.875% senior notes due 2032 and obtains $1.1B term loan facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.0B aggregate principal of 6.875% Senior Notes due September 1, 2032.","Entered $1.1B Incremental Term Loan A-1 Facility maturing April 28, 2028.","Net proceeds of ~$2.08B used to repay $950M Tranche B-1 Term Loans and $60M revolving loans.","Additional $350M revolving loans to be repaid; remainder for general corporate purposes.","Sixth Amendment removed cap on incremental term loan borrowings under credit agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217894,"accession_number":"0001206774-24-000776","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DaVita prices $1.0B of 6.875% Senior Notes due 2032; proceeds for debt repayment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.0B aggregate principal, 6.875% coupon, priced at par, due 2032; closing August 13, 2024.","Proceeds to repay Term Loan B-1 (2026) and revolver borrowings; includes accrued interest and fees.","Any remaining proceeds for general corporate purposes, including share repurchases and capex.","Offering is a private placement under Rule 144A/Reg S; not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217893,"accession_number":"0001206774-24-000769","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DaVita launches $1.0B senior notes due 2032; proceeds to repay Term Loan B-1 and revolver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.0B aggregate principal of Senior Notes due 2032 in a private offering under Rule 144A/Reg S.","Proceeds to repay outstanding Term Loan B-1 (maturing 2026) and revolving credit facility borrowings.","Also expects incremental $1.0B Term Loan A Facility substantially concurrently with closing.","Remaining proceeds may fund stock repurchases, working capital, and capital expenditures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217892,"accession_number":"0000927066-24-000126","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q2 2024 EPS $2.50, revenue $3.187B; raises adjusted EPS to $2.59","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $223M, diluted EPS $2.50; adjusted EPS $2.59 on revenue of $3.187B.","Operating income $506M; operating cash flow $799M, free cash flow $654M.","Extended maturity on $1.64B Term Loan B-1; repurchased 2.7M shares at $140.14 avg.","Six-month net income $462M vs $294M YoY; diluted EPS $5.15 vs $3.17."],"consensus_eps_estimate":null,"consensus_eps_actual":5.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":6257277000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237813,"accession_number":"0000927066-24-000115","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DaVita holds 2024 annual meeting; all director nominees elected, KPMG ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ten director nominees elected with majority support; broker non-votes of ~6.96M.","Ratification of KPMG as independent auditor for FY2024 passed: 75.7M for, 3.0M against.","Advisory vote on named executive officer compensation approved: 68.0M for, 3.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237812,"accession_number":"0000927066-24-000093","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"DaVita extends $1.64B term loan maturity to 2031, adds $658M incremental term loans","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended $1,640,250,847 of existing secured term loans from August 2026 to May 2031.","Added $657,884,309 in incremental term loans; proceeds used to repay non-extended portion.","Interest rate: Term SOFR + 200 bps or Base Rate + 100 bps.","Quarterly amortization at 1% per annum beginning December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237811,"accession_number":"0000927066-24-000089","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q1 2024 net income $240M, EPS $2.65; revenue $3.07B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.071B; operating income $484M; adjusted operating income $463M.","Diluted EPS $2.65 (up from $1.25 in Q1 2023); adjusted diluted EPS $2.38 (vs $1.58).","Operating cash flow $(135)M; free cash flow $(327)M due to working capital timing.","Repurchased 2.1M shares at average price $112.76 per share.","CEO cites continued operational discipline and investment in clinical excellence."],"consensus_eps_estimate":null,"consensus_eps_actual":2.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":3070555000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237810,"accession_number":"0000927066-24-000083","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"DaVita enters share repurchase agreement with Berkshire Hathaway to cap ownership at 45%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement requires DaVita to repurchase shares from Berkshire quarterly if ownership exceeds 45% of outstanding.","Immediate repurchase triggered if Berkshire ownership exceeds 49.5%.","Berkshire agrees to vote any shares beneficially owned above 40% as per board recommendation.","Existing standstill agreement from February 2022 remains in effect.","Repurchase price is volume-weighted average price paid by DaVita for open-market repurchases in the period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237809,"accession_number":"0000927066-24-000068","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DaVita appoints Dennis W. Pullin to Board, expands size to 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 10 to 11 members; Pullin appointed effective April 10, 2024.","Appointed to Compliance and Quality Committee as of April 10, 2024.","Will receive standard non-employee director compensation and indemnification per company policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255302,"accession_number":"0000927066-24-000005","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q4 revenue $3.15B, adj EPS $1.87; FY adj EPS $8.47, cash flow $2.06B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 consolidated revenue $3.146B; FY 2023 revenue $12.140B.","Q4 diluted EPS from continuing ops $1.62; adjusted $1.87, up from $1.62 in prior Q3.","FY 2023 diluted EPS $7.42 vs $5.71 in FY 2022; adjusted $8.47 vs $6.60.","Q4 operating cash flow $485M; FY 2023 operating cash flow $2.059B, free cash flow $1.236B.","Repurchased 2.9M shares at avg $97.82 in Q4; CEO cites strongest confidence since pre-COVID."],"consensus_eps_estimate":null,"consensus_eps_actual":7.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":12140147000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272778,"accession_number":"0000927066-23-000207","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q3 2023 adjusted EPS $2.85, revenue $3.1B, operating cash flow $661M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $2.62; adjusted diluted EPS $2.85, up from $2.08 in Q2 2023.","Consolidated revenue $3.1 billion; operating income $496M, adjusted operating income $525M.","Operating cash flow $661M; free cash flow $453M for the quarter.","Nine-month 2023 net income $541M vs $492M in prior year; diluted EPS $5.80 vs $5.07.","CEO Javier Rodriguez cited continued momentum and focus on operating discipline and patient care."],"consensus_eps_estimate":null,"consensus_eps_actual":5.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":8994400000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289622,"accession_number":"0000927066-23-000175","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita reports Q2 2023 revenue of $3.0B; diluted EPS $1.91, adjusted EPS $2.08","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $3.0B; operating income $405M; adjusted operating income $432M.","Diluted GAAP EPS $1.91; adjusted diluted EPS $2.08; free cash flow $260M.","Refinanced existing term loan and revolver with new $1.25B Term Loan A-1 and $1.5B revolver.","Six-month net income $294M vs $387M in prior year, a 24% decline.","CEO highlights strong clinical innovation and operational improvements; reaffirms full-year outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":3.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":5873068000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289621,"accession_number":"0000927066-23-000170","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DaVita appoints Christopher Berry as new Chief Accounting Officer, effective Aug 28, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Berry to succeed John D. Winstel as CAO; joins as Group VP, Accounting on Aug 28, 2023.","Berry previously served as SVP & CAO at Sonder Holdings and VP, Corporate Controller at Alaska Air Group.","Compensation: base salary $410k, RSU award $800k (vests 50% each on 3rd and 4th anniversary).","Eligible for annual performance bonus up to $300k starting 2024; guaranteed $205k for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289620,"accession_number":"0000927066-23-000162","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DaVita appoints Wendy L. Schoppert to Board of Directors, board expands to 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10 members; Wendy L. Schoppert appointed effective July 14, 2023.","She will serve on the Audit Committee and the Compliance and Quality Committee.","She receives standard non-employee director compensation and indemnification per existing policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310478,"accession_number":"0000927066-23-000152","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"DaVita shareholders elect directors, approve officer exculpation charter amendment at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected all nine director nominees; broker non-votes of 7.03M shares on contested proposals.","Ratified KPMG as independent auditor for FY2023: 78.18M for, 2.61M against, 46,294 abstain.","Advisory say-on-pay passed with 70.09M for; annual frequency of future votes approved with 72.48M for.","Approved charter amendment to exculpate certain officers from liability as permitted under Delaware law.","89.16% of outstanding shares (80.84M shares) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310477,"accession_number":"0000927066-23-000102","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q1 revenue $2.873B; GAAP EPS $1.25, adjusted EPS $1.58, down YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenues $2.873B; operating income $312M, adjusted operating income $352M.","GAAP diluted EPS $1.25 from continuing operations; adjusted diluted EPS $1.58.","Net income from continuing ops $116M, down from $162M YoY; adjusted net income $146M vs $165M.","Operating cash flow $463M, free cash flow $265M.","CEO to improving macro; no guidance change."],"consensus_eps_estimate":null,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":2872699000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310476,"accession_number":"0000927066-23-000096","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"DaVita refinances with $1.25B term loan and $1.5B revolver, extending maturities to 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.25B secured term loan A facility (New A-1) and $1.5B secured revolver replace existing $1.75B term loan and $1B revolver maturing Aug 2024.","Borrowings bear interest at Term SOFR + 200 bps (initially) for SOFR loans; Base Rate + 100 bps; commitment fee 0.30% on undrawn revolver.","Term loan amortizes at 2.5% p.a. in year 1, 5% in years 2-4, 7.5% in year 5; balance due at maturity.","Proceeds used to repay prior facilities, pay fees/expenses, and for working capital/general corporate purposes including repurchases and acquisitions.","Amendment includes provisions for ESG-linked KPIs that could adjust margins/commitment fees in the future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329137,"accession_number":"0000927066-23-000070","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DaVita CAO John Winstel to step down, effective no later than Sept 5, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Winstel notified DaVita on March 15, 2023 of his decision to step down as Chief Accounting Officer.","Transition period expected to end no later than September 5, 2023; Winstel will continue in role until then or until a successor is named.","Departure not due to any disagreement with the Company or its independent registered public accounting firm.","Company has commenced a search for Winstel's successor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329136,"accession_number":"0000927066-23-000009","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q4 2022: revenue $2.917B, adj. EPS $1.11; full-year adj. EPS $6.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $2.917B; full-year revenue $11.610B.","Q4 GAAP diluted EPS $0.59; adjusted diluted EPS $1.11.","Full-year GAAP diluted EPS $5.71; adjusted diluted EPS $6.60.","Q4 operating income $256M; adjusted operating income $317M.","CEO cites volume and labor challenges as headwinds for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":5.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":11609894000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346761,"accession_number":"0000927066-22-000164","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q3 EPS $1.13 vs $2.30 in prior quarter; cites COVID volume drag and labor pressure","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.949B; diluted EPS $1.13, adjusted diluted EPS $1.45.","Operating income $312M; adjusted operating income $351M.","Net income $105M, down from $225M in Q2 2022.","Repurchased 2.1M shares at avg cost $87.10.","CEO cites negative COVID volume trends and labor pressure as headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":5.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":8693006000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346760,"accession_number":"0000927066-22-000160","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2022-10-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"DaVita amends bylaws for DGCL changes and universal proxy rule compliance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amended and restated bylaws effective Oct. 14, 2022.","Changes reflect Delaware law updates on adjournment procedures and stockholder meeting lists.","Enhances disclosure requirements for stockholder nominations and proposals under Rule 14a-19.","New provisions require nominee interviews and notice of intent changes within two business days.","Amendments also include ministerial and conforming updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363136,"accession_number":"0000927066-22-000152","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2022-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DaVita expands board to 10, appoints Adam H. Schechter as director effective Sept 20, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 9 to 10 members; Adam H. Schechter appointed, effective September 20, 2022.","Schechter appointed to Audit Committee and Compliance and Quality Committee.","Will receive standard non-employee director compensation and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363135,"accession_number":"0000927066-22-000131","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q2 2022 EPS $2.30, revenue $2.93B; six-month net income down 27% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 revenue $2.927B, operating income $433M, diluted EPS $2.30 (vs Q1 2022 EPS $1.61).","Six-month net income $387M ($3.90/sh) vs $531M ($4.72/sh) in prior year, down 27%.","U.S. normalized non-acquired treatment growth was -1.9% YoY; per-day treatments up 0.9% QoQ.","Patient care costs per treatment improved to $247.14 (Q2) from $252.61 (Q1); G&A rose to $241M.","Repurchased 3.9M shares at $95.56 in Q2; additional 0.9M at $82.94 in July."],"consensus_eps_estimate":null,"consensus_eps_actual":3.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":5744312000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382855,"accession_number":"0000927066-22-000121","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DaVita shareholders elect 9 directors, ratify KPMG, approve exec compensation, reject political spending proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected with 78-99% of votes cast, including Jason M. Hollar and Gregory J. Moore, MD, PhD.","KPMG LLP ratified as independent auditor for FY2022 with 81,889,042 for, 3,026,111 against.","Advisory vote on named executive officer compensation approved: 73,732,100 for, 4,851,929 against.","Shareholder proposal on political contributions disclosure rejected: 18,845,131 for, 59,567,699 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382854,"accession_number":"0000927066-22-000110","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"DaVita and Medtronic form joint venture to create independent kidney-care device company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Equal equity stakes; Medtronic contributes Renal Care Solutions; DaVita pays $75M cash and $25M other assets.","Each contributes $200M cash to launch NewCo; up to $300M milestone payments possible through 2028.","Expected close in 2023, subject to HSR and other regulatory approvals.","DaVita expects quarterly charges ~$20M after close, decreasing to zero in 2-3 years as NewCo reaches breakeven.","Independent management and six-person board with two directors from each parent plus two independents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382853,"accession_number":"0000927066-22-000075","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q1 2022 EPS $1.61, down 10% from prior quarter; revenue $2.818B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS of $1.61 vs $1.79 in Q4 2021 and $2.09 in Q1 2021; adjusted EPS $1.61.","Consolidated revenue of $2.818 billion for the quarter.","Operating income of $338 million; operating cash flow $322 million, free cash flow $147 million.","Repurchased 2.1 million shares at avg cost $110.90 per share.","COVID-19 Omicron variant caused higher patient mortality and missed treatments, plus wage inflation."],"consensus_eps_estimate":null,"consensus_eps_actual":1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":2817555000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382852,"accession_number":"0000927066-22-000046","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DaVita expands board to 10, appoints Jason M. Hollar as director and Audit Committee member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from nine to ten members effective May 6, 2022.","Jason M. Hollar appointed as director, effective May 6, 2022.","Hollar also appointed to the Audit Committee of the Board.","Will receive standard non-employee director compensation per existing policy.","Company expects to enter standard indemnification agreement with Hollar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400695,"accession_number":"0000927066-22-000006","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2022-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q4 2021 adjusted EPS $2.02 (+21% YoY); full-year revenue $11.6B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 diluted EPS from cont. ops $1.79 (+7.2% YoY); adjusted diluted EPS $2.02 (+21.0% YoY).","Full-year 2021 diluted EPS $8.90 (+39.3% YoY); adjusted diluted EPS $9.13 (+25.8% YoY).","Q4 revenue $2.944B; full-year $11.619B. Operating income Q4 $389M; full-year $1,797M.","Repurchased 6.1M shares in Q4 at avg $105.52; full-year 13.9M shares at avg $111.41.","Operating cash flow from cont. ops: Q4 $530M; full-year $1,931M. Free cash flow Q4 $290M; full-year $1,133M."],"consensus_eps_estimate":null,"consensus_eps_actual":8.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":11618797000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400694,"accession_number":"0000927066-22-000002","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DaVita restates standstill with Berkshire Hathaway; caps additional purchases at 25% ownership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Berkshire agrees not to buy additional DaVita shares if beneficial ownership exceeds 25% of outstanding common stock.","Shares over 40% must be voted as DaVita board recommends; shares between 15% and 40% will be voted proportionally after Buffett/Weschler exit.","Existing 2013 standstill amended; also restricts Berkshire from transferring >5% of shares in a single transaction without DaVita consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419667,"accession_number":"0000927066-21-000189","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2021-12-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DaVita Board approves $2B increase in share repurchase authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized additional $2B for share repurchases, no expiration date.","Existing $1B authorization from Dec 2020 remains in place; total capacity increased.","Repurchases may occur via open market, private transactions, ASRs, or derivatives.","Company is not obligated to repurchase any shares; program may be suspended.","Repurchases subject to limitations under existing senior secured credit facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419666,"accession_number":"0000927066-21-000164","cik":927066,"company_name":"DAVITA INC.","ticker":"DVA","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DaVita Q3 2021 EPS $2.36 (+84% YoY); revenue $2.938B; repurchased 2.7M shares","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS from continuing ops $2.36 vs $1.28 prior year; adjusted EPS $2.36 vs $1.80.","Consolidated revenue $2.938B; operating income $475M; net income $260M from continuing ops.","Operating cash flow $567M; free cash flow $358M from continuing operations.","Repurchased 2.731M shares at avg cost $123.14 per share during the quarter.","CEO cites strong results despite COVID-19 resurgence and challenging labor market."],"consensus_eps_estimate":null,"consensus_eps_actual":7.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":8674830000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12513863873.422098,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-10-28T23:59:59+00:00|419666"}